These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 30874904)

  • 1. Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia.
    Roug AS; Ommen HB
    Curr Treat Options Oncol; 2019 Mar; 20(4):28. PubMed ID: 30874904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using minimal (measurable) residual disease assessments to guide decision-making for timing of allogeneic transplantation in acute myeloid leukemia.
    Fasan O
    Curr Opin Hematol; 2019 Nov; 26(6):413-420. PubMed ID: 31503019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
    Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
    Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
    Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
    Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
    Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid Leukemia.
    Blackmon AL; Hourigan CS
    Acta Haematol; 2024; 147(2):133-146. PubMed ID: 38035547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal Residual Disease in Acute Myeloid Leukemia.
    Sung PJ; Luger SM
    Curr Treat Options Oncol; 2017 Jan; 18(1):1. PubMed ID: 28110381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
    Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
    Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.
    Zhou Y; Othus M; Araki D; Wood BL; Radich JP; Halpern AB; Mielcarek M; Estey EH; Appelbaum FR; Walter RB
    Leukemia; 2016 Jul; 30(7):1456-64. PubMed ID: 27012865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal/Measurable Residual Disease Monitoring in
    Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors.
    Narlı Özdemir Z; Şahin U; Dalva K; Baltacı MA; Uslu A; Öztürk C; Cengiz Seval G; Toprak SK; Kurt Yüksel M; Topçuoğlu P; Arslan Ö; Özcan M; Beksaç M; İlhan O; Gürman G; Civriz Bozdağ S
    Turk J Haematol; 2021 Jun; 38(2):111-118. PubMed ID: 33112099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia.
    Wong ZC; Dillon LW; Hourigan CS
    Best Pract Res Clin Haematol; 2023 Jun; 36(2):101468. PubMed ID: 37353292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
    Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
    Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of pre-transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML.
    Klyuchnikov E; Christopeit M; Badbaran A; Bacher U; Fritzsche-Friedland U; von Pein UM; Wolschke C; Kröger N
    Eur J Haematol; 2021 May; 106(5):606-615. PubMed ID: 33249666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should patients with acute myeloid leukemia and measurable residual disease be transplanted in first complete remission?
    Buccisano F; Walter RB
    Curr Opin Hematol; 2017 Mar; 24(2):132-138. PubMed ID: 27930388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia.
    Czyz A; Nagler A
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
    Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.
    Xiao W; Petrova-Drus K; Roshal M
    Surg Pathol Clin; 2019 Sep; 12(3):671-686. PubMed ID: 31352980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.
    Kayser S; Benner A; Thiede C; Martens U; Huber J; Stadtherr P; Janssen JW; Röllig C; Uppenkamp MJ; Bochtler T; Hegenbart U; Ehninger G; Ho AD; Dreger P; Krämer A
    Blood Cancer J; 2016 Jul; 6(7):e449. PubMed ID: 27471865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia.
    Aitken MJL; Ravandi F; Patel KP; Short NJ
    J Hematol Oncol; 2021 Sep; 14(1):137. PubMed ID: 34479626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.